Real Clinical Practice of Using Afatinib Therapy in NSCLC Patients with an Acquired EGFR T790M Mutation
To describe real clinical outcomes when using afatinib therapy to treat non-small cell lung cancer patients who have an acquired EGFR T790M mutation. A retrospective chart review was conducted from January 2013 to November 2017 sourced from 15 medical institutes that cover a population of three mill...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2018-09, Vol.38 (9), p.5409-5415 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 5415 |
|---|---|
| container_issue | 9 |
| container_start_page | 5409 |
| container_title | Anticancer research |
| container_volume | 38 |
| creator | Miyazaki, Kunihiko Tamura, Tomohiro Kaburagi, Takayuki Saito, Kazuhito Inagaki, Masaharu Yamashita, Takaaki Ichimura, Hideo Nawa, Takeshi Endo, Takeo Hayashihara, Kenji Kimura, Masaki Kurishima, Koichi Nakamura, Hiroyuki Furukawa, Kinya Kikuchi, Norihiro Satoh, Hiroaki Hizawa, Nobuyuki |
| description | To describe real clinical outcomes when using afatinib therapy to treat non-small cell lung cancer patients who have an acquired EGFR T790M mutation.
A retrospective chart review was conducted from January 2013 to November 2017 sourced from 15 medical institutes that cover a population of three million people.
There were 74 patients who met the above-mentioned criteria. Treatment outcomes with afatinib, in patients with or without tyrosine kinase inhibitor (TKI) therapy prior to afatinib, were similar to previously reported clinical trials. Stratification of patients by the presence or absence of TKI pretreatment before afatinib, and the presence or absence of an acquired T790M mutation found no statistical difference in overall survival.
This population-based study found that the disadvantages of pretreatment before afatinib, and absence of an acquired T790M EGFR mutation, could be overcome by an appropriate treatment strategy in clinical practice. |
| doi_str_mv | 10.21873/anticanres.12871 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2101271880</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2101271880</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-8b0767f9bd8574afe2739dd3c62cc126e1a72b5f6977da9be25f788c8f6892313</originalsourceid><addsrcrecordid>eNpdkU1LAzEQhoMoWj9-gBcJePGymo9uJjmWpVWhVdF6XrLZRFe22ZrsIv33Bq0KnuYwz_swzIvQKSWXjErgV9r3jdE-2HhJmQS6g0YUFM0g52QXjQjLSQaE5AfoMMY3QoRQku-jA06oGlMlRujl0eoWF23jk6jFD0GbpLS4c_g5Nv4FT5zu07LCy1cb9HqDG4_vnop5gR_Swvo-4o-mf8Xa44l5H5pgazy9nj3iJSiywIuhT1jnj9Ge0220J9t5hJ5n02Vxk83vr2-LyTwzHFifyYqAAKeqWuYw1s4y4KquuRHMGMqEpRpYlTuhAGqtKstyB1Ia6YRUjFN-hC6-vevQvQ829uWqica2rfa2G2LJKKEMqJQkoef_0LduCD5dlyguBYHxWCaKflMmdDEG68p1aFY6bEpKyq8Wyr8Wyq8WUuZsax6qla1_Ez9v558Z84MS</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2138607448</pqid></control><display><type>article</type><title>Real Clinical Practice of Using Afatinib Therapy in NSCLC Patients with an Acquired EGFR T790M Mutation</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Miyazaki, Kunihiko ; Tamura, Tomohiro ; Kaburagi, Takayuki ; Saito, Kazuhito ; Inagaki, Masaharu ; Yamashita, Takaaki ; Ichimura, Hideo ; Nawa, Takeshi ; Endo, Takeo ; Hayashihara, Kenji ; Kimura, Masaki ; Kurishima, Koichi ; Nakamura, Hiroyuki ; Furukawa, Kinya ; Kikuchi, Norihiro ; Satoh, Hiroaki ; Hizawa, Nobuyuki</creator><creatorcontrib>Miyazaki, Kunihiko ; Tamura, Tomohiro ; Kaburagi, Takayuki ; Saito, Kazuhito ; Inagaki, Masaharu ; Yamashita, Takaaki ; Ichimura, Hideo ; Nawa, Takeshi ; Endo, Takeo ; Hayashihara, Kenji ; Kimura, Masaki ; Kurishima, Koichi ; Nakamura, Hiroyuki ; Furukawa, Kinya ; Kikuchi, Norihiro ; Satoh, Hiroaki ; Hizawa, Nobuyuki</creatorcontrib><description>To describe real clinical outcomes when using afatinib therapy to treat non-small cell lung cancer patients who have an acquired EGFR T790M mutation.
A retrospective chart review was conducted from January 2013 to November 2017 sourced from 15 medical institutes that cover a population of three million people.
There were 74 patients who met the above-mentioned criteria. Treatment outcomes with afatinib, in patients with or without tyrosine kinase inhibitor (TKI) therapy prior to afatinib, were similar to previously reported clinical trials. Stratification of patients by the presence or absence of TKI pretreatment before afatinib, and the presence or absence of an acquired T790M mutation found no statistical difference in overall survival.
This population-based study found that the disadvantages of pretreatment before afatinib, and absence of an acquired T790M EGFR mutation, could be overcome by an appropriate treatment strategy in clinical practice.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>DOI: 10.21873/anticanres.12871</identifier><identifier>PMID: 30194196</identifier><language>eng</language><publisher>Greece: International Institute of Anticancer Research</publisher><subject>c-Met protein ; Clinical medicine ; Clinical trials ; Enzyme inhibitors ; Epidermal growth factor receptors ; Lung cancer ; Medical research ; Mutation ; Non-small cell lung carcinoma ; Patients ; Population (statistical) ; Population studies ; Protein-tyrosine kinase ; Therapy ; Tyrosine</subject><ispartof>Anticancer research, 2018-09, Vol.38 (9), p.5409-5415</ispartof><rights>Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</rights><rights>Copyright International Institute of Anticancer Research Sep 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-8b0767f9bd8574afe2739dd3c62cc126e1a72b5f6977da9be25f788c8f6892313</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30194196$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miyazaki, Kunihiko</creatorcontrib><creatorcontrib>Tamura, Tomohiro</creatorcontrib><creatorcontrib>Kaburagi, Takayuki</creatorcontrib><creatorcontrib>Saito, Kazuhito</creatorcontrib><creatorcontrib>Inagaki, Masaharu</creatorcontrib><creatorcontrib>Yamashita, Takaaki</creatorcontrib><creatorcontrib>Ichimura, Hideo</creatorcontrib><creatorcontrib>Nawa, Takeshi</creatorcontrib><creatorcontrib>Endo, Takeo</creatorcontrib><creatorcontrib>Hayashihara, Kenji</creatorcontrib><creatorcontrib>Kimura, Masaki</creatorcontrib><creatorcontrib>Kurishima, Koichi</creatorcontrib><creatorcontrib>Nakamura, Hiroyuki</creatorcontrib><creatorcontrib>Furukawa, Kinya</creatorcontrib><creatorcontrib>Kikuchi, Norihiro</creatorcontrib><creatorcontrib>Satoh, Hiroaki</creatorcontrib><creatorcontrib>Hizawa, Nobuyuki</creatorcontrib><title>Real Clinical Practice of Using Afatinib Therapy in NSCLC Patients with an Acquired EGFR T790M Mutation</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>To describe real clinical outcomes when using afatinib therapy to treat non-small cell lung cancer patients who have an acquired EGFR T790M mutation.
A retrospective chart review was conducted from January 2013 to November 2017 sourced from 15 medical institutes that cover a population of three million people.
There were 74 patients who met the above-mentioned criteria. Treatment outcomes with afatinib, in patients with or without tyrosine kinase inhibitor (TKI) therapy prior to afatinib, were similar to previously reported clinical trials. Stratification of patients by the presence or absence of TKI pretreatment before afatinib, and the presence or absence of an acquired T790M mutation found no statistical difference in overall survival.
This population-based study found that the disadvantages of pretreatment before afatinib, and absence of an acquired T790M EGFR mutation, could be overcome by an appropriate treatment strategy in clinical practice.</description><subject>c-Met protein</subject><subject>Clinical medicine</subject><subject>Clinical trials</subject><subject>Enzyme inhibitors</subject><subject>Epidermal growth factor receptors</subject><subject>Lung cancer</subject><subject>Medical research</subject><subject>Mutation</subject><subject>Non-small cell lung carcinoma</subject><subject>Patients</subject><subject>Population (statistical)</subject><subject>Population studies</subject><subject>Protein-tyrosine kinase</subject><subject>Therapy</subject><subject>Tyrosine</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpdkU1LAzEQhoMoWj9-gBcJePGymo9uJjmWpVWhVdF6XrLZRFe22ZrsIv33Bq0KnuYwz_swzIvQKSWXjErgV9r3jdE-2HhJmQS6g0YUFM0g52QXjQjLSQaE5AfoMMY3QoRQku-jA06oGlMlRujl0eoWF23jk6jFD0GbpLS4c_g5Nv4FT5zu07LCy1cb9HqDG4_vnop5gR_Swvo-4o-mf8Xa44l5H5pgazy9nj3iJSiywIuhT1jnj9Ge0220J9t5hJ5n02Vxk83vr2-LyTwzHFifyYqAAKeqWuYw1s4y4KquuRHMGMqEpRpYlTuhAGqtKstyB1Ia6YRUjFN-hC6-vevQvQ829uWqica2rfa2G2LJKKEMqJQkoef_0LduCD5dlyguBYHxWCaKflMmdDEG68p1aFY6bEpKyq8Wyr8Wyq8WUuZsax6qla1_Ez9v558Z84MS</recordid><startdate>201809</startdate><enddate>201809</enddate><creator>Miyazaki, Kunihiko</creator><creator>Tamura, Tomohiro</creator><creator>Kaburagi, Takayuki</creator><creator>Saito, Kazuhito</creator><creator>Inagaki, Masaharu</creator><creator>Yamashita, Takaaki</creator><creator>Ichimura, Hideo</creator><creator>Nawa, Takeshi</creator><creator>Endo, Takeo</creator><creator>Hayashihara, Kenji</creator><creator>Kimura, Masaki</creator><creator>Kurishima, Koichi</creator><creator>Nakamura, Hiroyuki</creator><creator>Furukawa, Kinya</creator><creator>Kikuchi, Norihiro</creator><creator>Satoh, Hiroaki</creator><creator>Hizawa, Nobuyuki</creator><general>International Institute of Anticancer Research</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>201809</creationdate><title>Real Clinical Practice of Using Afatinib Therapy in NSCLC Patients with an Acquired EGFR T790M Mutation</title><author>Miyazaki, Kunihiko ; Tamura, Tomohiro ; Kaburagi, Takayuki ; Saito, Kazuhito ; Inagaki, Masaharu ; Yamashita, Takaaki ; Ichimura, Hideo ; Nawa, Takeshi ; Endo, Takeo ; Hayashihara, Kenji ; Kimura, Masaki ; Kurishima, Koichi ; Nakamura, Hiroyuki ; Furukawa, Kinya ; Kikuchi, Norihiro ; Satoh, Hiroaki ; Hizawa, Nobuyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-8b0767f9bd8574afe2739dd3c62cc126e1a72b5f6977da9be25f788c8f6892313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>c-Met protein</topic><topic>Clinical medicine</topic><topic>Clinical trials</topic><topic>Enzyme inhibitors</topic><topic>Epidermal growth factor receptors</topic><topic>Lung cancer</topic><topic>Medical research</topic><topic>Mutation</topic><topic>Non-small cell lung carcinoma</topic><topic>Patients</topic><topic>Population (statistical)</topic><topic>Population studies</topic><topic>Protein-tyrosine kinase</topic><topic>Therapy</topic><topic>Tyrosine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miyazaki, Kunihiko</creatorcontrib><creatorcontrib>Tamura, Tomohiro</creatorcontrib><creatorcontrib>Kaburagi, Takayuki</creatorcontrib><creatorcontrib>Saito, Kazuhito</creatorcontrib><creatorcontrib>Inagaki, Masaharu</creatorcontrib><creatorcontrib>Yamashita, Takaaki</creatorcontrib><creatorcontrib>Ichimura, Hideo</creatorcontrib><creatorcontrib>Nawa, Takeshi</creatorcontrib><creatorcontrib>Endo, Takeo</creatorcontrib><creatorcontrib>Hayashihara, Kenji</creatorcontrib><creatorcontrib>Kimura, Masaki</creatorcontrib><creatorcontrib>Kurishima, Koichi</creatorcontrib><creatorcontrib>Nakamura, Hiroyuki</creatorcontrib><creatorcontrib>Furukawa, Kinya</creatorcontrib><creatorcontrib>Kikuchi, Norihiro</creatorcontrib><creatorcontrib>Satoh, Hiroaki</creatorcontrib><creatorcontrib>Hizawa, Nobuyuki</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miyazaki, Kunihiko</au><au>Tamura, Tomohiro</au><au>Kaburagi, Takayuki</au><au>Saito, Kazuhito</au><au>Inagaki, Masaharu</au><au>Yamashita, Takaaki</au><au>Ichimura, Hideo</au><au>Nawa, Takeshi</au><au>Endo, Takeo</au><au>Hayashihara, Kenji</au><au>Kimura, Masaki</au><au>Kurishima, Koichi</au><au>Nakamura, Hiroyuki</au><au>Furukawa, Kinya</au><au>Kikuchi, Norihiro</au><au>Satoh, Hiroaki</au><au>Hizawa, Nobuyuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Real Clinical Practice of Using Afatinib Therapy in NSCLC Patients with an Acquired EGFR T790M Mutation</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2018-09</date><risdate>2018</risdate><volume>38</volume><issue>9</issue><spage>5409</spage><epage>5415</epage><pages>5409-5415</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>To describe real clinical outcomes when using afatinib therapy to treat non-small cell lung cancer patients who have an acquired EGFR T790M mutation.
A retrospective chart review was conducted from January 2013 to November 2017 sourced from 15 medical institutes that cover a population of three million people.
There were 74 patients who met the above-mentioned criteria. Treatment outcomes with afatinib, in patients with or without tyrosine kinase inhibitor (TKI) therapy prior to afatinib, were similar to previously reported clinical trials. Stratification of patients by the presence or absence of TKI pretreatment before afatinib, and the presence or absence of an acquired T790M mutation found no statistical difference in overall survival.
This population-based study found that the disadvantages of pretreatment before afatinib, and absence of an acquired T790M EGFR mutation, could be overcome by an appropriate treatment strategy in clinical practice.</abstract><cop>Greece</cop><pub>International Institute of Anticancer Research</pub><pmid>30194196</pmid><doi>10.21873/anticanres.12871</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2018-09, Vol.38 (9), p.5409-5415 |
| issn | 0250-7005 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2101271880 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | c-Met protein Clinical medicine Clinical trials Enzyme inhibitors Epidermal growth factor receptors Lung cancer Medical research Mutation Non-small cell lung carcinoma Patients Population (statistical) Population studies Protein-tyrosine kinase Therapy Tyrosine |
| title | Real Clinical Practice of Using Afatinib Therapy in NSCLC Patients with an Acquired EGFR T790M Mutation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T02%3A02%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Real%20Clinical%20Practice%20of%20Using%20Afatinib%20Therapy%20in%20NSCLC%20Patients%20with%20an%20Acquired%20EGFR%20T790M%20Mutation&rft.jtitle=Anticancer%20research&rft.au=Miyazaki,%20Kunihiko&rft.date=2018-09&rft.volume=38&rft.issue=9&rft.spage=5409&rft.epage=5415&rft.pages=5409-5415&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/10.21873/anticanres.12871&rft_dat=%3Cproquest_cross%3E2101271880%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2138607448&rft_id=info:pmid/30194196&rfr_iscdi=true |